Toripalimab Combined With Radiotherapy and S-1 for Older Patients With Esophageal Cancer

This study is testing a combination of immunotherapy (toripalimab), oral chemotherapy (S-1), and radiation therapy for older patients (65+) with esophageal cancer who cannot or choose not to have surgery. **You may be eligible if...** - You are 65 or older - You have confirmed esophageal cancer (stage I–III) - You are unable to have surgery or have chosen not to - You are well enough to tolerate immunotherapy combined with chemotherapy and radiation (ECOG 0–2) - Your blood counts, liver, kidney, heart, and lung function are within acceptable ranges - You have at least one measurable tumor - You have a life expectancy of at least 6 months **You may NOT be eligible if...** - Your cancer has spread to distant organs - You have serious heart, lung, liver, or kidney problems - You are pregnant or breastfeeding - You have a history of severe immune-related conditions Talk to your doctor to see if this trial is right for you.